Tonix Tonmya TNX-102 SL Fibromyalgia 2024

Tonix Pharmaceuticals presents Tonmya (TNX-102 SL), an FDA-conditionally accepted drug candidate for fibromyalgia management. The presentation details fibromyalgia as a chronic overlapping pain condition and nociplastic syndrome, positioning Tonmya within the CNS portfolio alongside existing FDA-approved fibromyalgia treatments.